Image

Global Adalimumab Biosimilar Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Medical Devices
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Adalimumab Biosimilar Market, By Product (Exemptia, Adalirel, Cipleumab, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Others) – Industry Trends and Forecast to 2029.

Global Adalimumab Biosimilar Market

Adalimumab Biosimilar Market Analysis and Size

Biosimilars are also known as biologics with a subsequent entrance. Adalimumab is a medication used to treat number of illnesses, including rheumatoid arthritis and psoriatic arthritis. Humira and the biosimilar adalimumab both reduce inflammation effectively and safely. The launch of new biosimilars will result in a drop in medicine prices on the worldwide market, which would then fuelmarket demand. During the forecast period, this is anticipated to support the expansion of the global market for adalimumab biosimilars.

Data Bridge Market Research analyses that the adalimumab biosimilar market which was USD 1.54 billion in 2021, would rocket up to USD 37.5 billion by 2029, and is expected to undergo a CAGR of 49 % during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Adalimumab Biosimilar Market Scope and Segmentation      

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product (Exemptia, Adalirel, Cipleumab, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Glenmark (India), Zydus Cadila (India), Torrent Pharmaceuticals Ltd. (India), Reliance Life Sciences (India), Emcure Pharmaceuticals Ltd (India), Cipla Inc. (India), Hetero (India), AET BioTech (Germany), Coherus Biosciences (U.S.), Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan), Momenta Pharmaceuticals (U.S.), Oncobiologics (U.S.), Pfizer Inc. (U.S.), Samsung Bioepsis (South Korea), Sandoz International GmbH (Switzerland)

Market Opportunities

  • Rising incidence of rheumatoid arthritis
  • Growing geriatric population

Market Definition

A monoclonal antibody called adalimumab is used to treat autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. By reducing joint swelling, this medication aids in preventing future joint damage and maintaining joint function. As the prevalence of arthritis among the global population rises, the market for adalimumab biosimilar is anticipated to expand in the forecast period.

Adalimumab Biosimilar Market Dynamics

Drivers

  • Rising per capita income

The market for adalimumab biosimilar products will be fuelled by the rapid adoption of digitalization between professionals and prisoners. Additionally, it is anticipated that rising per capita income and thriving subsistence levels will encourage the market.

  • Growing market for biosimilar medicines

Numerous biopharmaceuticals conforming off-license during the ensuing years, and a growing market for biosimilar medicines because to their affordability, are a few more factors driving the industry growth.

Opportunities

  • Increase in the number of research and development activities  

The market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the market growth.

Restraints/Challenges

On the other hand, the high cost associated with biosimilars will obstruct the market's growth rate.

This adalimumab biosimilar market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adalimumab biosimilar market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Adalimumab Biosimilar Market Scope

The adalimumab biosimilar market is segmented on the basis of product and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Exemptia
  • Adalirel
  • Cipleumab
  • Others

Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

Adalimumab Biosimilar Market Regional Analysis/Insights

The adalimumab biosimilar market is analysed and market size insights and trends are provided by country, product and distribution channel as referenced above.

The countries covered in the adalimumab biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the adalimumab biosimilar market due to the proximity of multiple extensive experimentation laboratories.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the province's extensive commercial advancements and growing biotechnology corporations.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Adalimumab Biosimilar Market Share Analysis

The adalimumab biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adalimumab biosimilar market.

Some of the major players operating in the adalimumab biosimilar market are:

  • Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany)
  • Amgen Inc. (U.S.)
  • Boehringer Ingelheim International GmbH (Germany)
  • Glenmark (India)
  • Zydus Cadila (India)
  • Torrent Pharmaceuticals Ltd. (India)
  • Reliance Life Sciences (India)
  • Emcure Pharmaceuticals Ltd (India)
  • Cipla Inc. (India)
  • Hetero (India)
  • AET BioTech (Germany)
  • Coherus Biosciences (U.S.)
  • Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan)
  • Momenta Pharmaceuticals (U.S.)
  • Oncobiologics (U.S.)
  • Pfizer Inc. (U.S.)
  • Samsung Bioepsis (South Korea)
  • Sandoz International GmbH (Switzerland)


SKU-
Why Choose Us


Frequently Asked Questions

The adalimumab biosimilar market value is projected USD 37.5 billion by 2029.
The adalimumab biosimilar market is projected to grow at a CAGR of 49 % during the forecast period of 2022-2029.
On the basis of product, the Adalimumab Biosimilar Market is segmented into Exemptia, Adalirel, Cipleumab, Others.
The major players operating in the Adalimumab Biosimilar Market are Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Glenmark (India), Zydus Cadila (India), Torrent Pharmaceuticals Ltd. (India), Reliance Life Sciences (India), Emcure Pharmaceuticals Ltd (India), Cipla Inc. (India), Hetero (India), AET BioTech (Germany), Coherus Biosciences (U.S.), Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan), Momenta Pharmaceuticals (U.S.), Oncobiologics (U.S.), Pfizer Inc. (U.S.), Samsung Bioepsis (South Korea), Sandoz International GmbH (Switzerland).